The U.S. drug regulator approved Palatin Technologies and Amag Pharmaceuticals’ drug to restore sexual desire in premenopausal women.
Danaher Corp. said it would buy medical diagnostics company Cepheid in a deal valued at $4 billion that will strengthen its presence in molecular diagnostics.
Valeant Pharmaceuticals International Inc will cut its sales force for Addyi, a treatment aimed at female sexual dysfunction, as well as some employees who sell dermatology products, according to an internal memo seen by Reuters. The memo said that its contract with an outside sales force ends on April 15 and will not be […]
Remember when the FDA rejected drugs? We just got treated to a whole lot of drama this week as to whether Addyi, a drug to boost women’s libidos, would be approved. But based on the data, that approval was probably a foregone conclusion. As recently as 2008, companies filing applications to sell never-before-marketed drugs, which […]
Sprout Pharmaceuticals continues to remain atop the news cycles just days after the U.S. Food and Drug Administration (FDA) approved the first female sex-drive drug, Addyi. Today Canadian-based Valeant Pharma (VRX) announced it was acquiring the now Raleigh, N.C.-based company for $1 billion in cash, plus a share of future profits based upon the achievement […]
The FDA has approved a controversial drug designed to enhance a woman’s sexual drive. Addyi (generic name: flibanserin), from Sprout Pharmaceuticals, acts in the brain to enhance a woman’s libido. By taking one pill a day for a month, clinical trials showed that women on Addyi on average increased their number of satisfying sexual events […]